These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22393543)

  • 61. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
    Phanuphak N; Ananworanich J; Teeratakulpisarn N; Jadwattanakul T; Kerr SJ; Chomchey N; Hongchookiat P; Mathajittiphun P; Pinyakorn S; Rungrojrat P; Praihirunyakit P; Gerschenson M; Phanuphak P; Valcour V; Kim JH; Shikuma C;
    Antivir Ther; 2012; 17(8):1521-31. PubMed ID: 23220732
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Magnitude and causes of first-line antiretroviral therapy regimen changes among HIV patients in Ethiopia: a systematic review and meta-analysis.
    Ataro Z; Motbaynor B; Weldegebreal F; Sisay M; Tesfa T; Mitiku H; Marami D; Teklemariam Z; Shewamene Z
    BMC Pharmacol Toxicol; 2019 Nov; 20(1):63. PubMed ID: 31675986
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mitochondrial toxicities of nucleoside analogue reverse transcriptase inhibitors in AIDS cases.
    Marfatia YS; Talwar M; Agrawal M; Sharma A; Mehta K
    Indian J Sex Transm Dis AIDS; 2014; 35(2):96-9. PubMed ID: 26396441
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.
    van Leth F; Wit FW; Reiss P; Schattenkerk JK; van der Ende ME; Schneider MM; Mulder JW; Frissen PH; de Wolf F; Lange JM
    HIV Med; 2004 Mar; 5(2):74-81. PubMed ID: 15012645
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 66. K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data.
    Recordon-Pinson P; Papuchon J; Reigadas S; Deshpande A; Fleury H
    PLoS One; 2012; 7(5):e36549. PubMed ID: 22615779
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.
    Cesar C; Shepherd BE; Krolewiecki AJ; Fink VI; Schechter M; Tuboi SH; Wolff M; Pape JW; Leger P; Padgett D; Madero JS; Gotuzzo E; Sued O; McGowan CC; Masys DR; Cahn PE;
    PLoS One; 2010 Jun; 5(6):e10490. PubMed ID: 20531956
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effect of highly active antiretroviral therapy on liver function in human immunodeficiency virus-infected pediatric patients with or without hepatitis virus co-infection.
    Wu L; Jin C; Bai S; Davies H; Rao H; Liang Y; Wu N
    J Res Med Sci; 2015 Feb; 20(2):127-32. PubMed ID: 25983763
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
    Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
    HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics.
    Amoroso A; Etienne-Mesubi M; Edozien A; Ojoo S; Sheneberger R; Obiefune M; Hossain MB; Stafford K; Redfield RR
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):314-20. PubMed ID: 22343178
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
    Sadeghi L; Moallemi S; Tabatabai RA; Esmaeilzadeh A; Ahsani-Nasab S; Ahmadi NE; Bayanolhagh S; Lolaie M; Narouei A; SeyedAlinaghi S; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):207-213. PubMed ID: 29308748
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Generic antiretroviral drug use in HIV-infected patients: A cohort study from the French health insurance database.
    Rwagitinywa J; Lapeyre-Mestre M; Bourrel R; Sommet A
    Therapie; 2018; 73(3):257-266. PubMed ID: 29195713
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies.
    Ayele TA; Worku A; Kebede Y; Alemu K; Kasim A; Shkedy Z
    Syst Rev; 2017 Aug; 6(1):173. PubMed ID: 28841912
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.
    Buchacz K; Weidle PJ; Moore D; Were W; Mermin J; Downing R; Kigozi A; Borkowf CB; Ndazima V; Brooks JT
    J Acquir Immune Defic Syndr; 2008 Mar; 47(3):304-11. PubMed ID: 18398971
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Management of common adverse effects in the era of highly active antiretroviral therapy in south east Ethiopia.
    Abdella SH; Wabe NT; Yesuf EA
    N Am J Med Sci; 2011 Nov; 3(11):499-502. PubMed ID: 22361495
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Initial antiretroviral therapy regimen and risk of heart failure: Erratum.
    AIDS; 2024 Aug; 38(10):1608. PubMed ID: 38990320
    [No Abstract]   [Full Text] [Related]  

  • 80. Causes for antiretroviral regimen change among HIV/AIDS patients in Addis Ababa, Ethiopia.
    Jima YT; Angamo MT; Wabe NT
    Tanzan J Health Res; 2013 Jan; 15(1):11-8. PubMed ID: 26591668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.